Breakthrough T1D Blog

JDRF’s mission of improving lives and curing type 1 diabetes (T1D) cannot be achieved alone. It requires us to engage with stakeholders who believe in what we have set out to do and are able to help drive our mission forward – and this group includes regulators. JDRF recognizes the importance of engaging with regulators in order to to help shape and provide clear and reasonable pathways to scientific research and therapy approvals for T1D treatment and cure therapies.

Halloween day will never be the same for Conrad Pow as that was the day in 2018 when his daughter Chloe was diagnosed with type 1 diabetes (T1D).

This past month, as part of JDRF’s #AccessforAll campaign, British Columbians impacted by type 1 diabetes (T1D) came together with patient advocates, clinicians and elected officials to discuss the benefits of continuous glucose monitoring (CGM) and flash glucose monitoring (Flash GM) devices, and the need to cover these technologies under B.C. Pharmacare.

Our #AccessForAll campaign has been keeping busy, finding new and creative ways to advocate government officials at the provincial level despite the constraints of COVID-19. To everyone who has supported by volunteering time, talents or donations– thank you.

March 8 marks International Women’s Day (IWD) globally. This 2021 campaign theme is #ChooseToChallenge.

For anyone impacted by type 1 diabetes (T1D), the term ‘biosimilars’ is one that will become increasingly familiar now that the patents of some biologic insulins are expiring. This means that biosimilar versions of these insulins may be approved, and some are already on the North American market.

Like most parents after their child has been diagnosed with Type 1 diabetes, Cindy Voss found herself overwhelmed, anxious and exhausted. With an active 10-year old whose glucose levels would drop quickly and unexpectedly, Cindy found herself constantly worrying and would get up every couple of hours throughout the night to prick her son Mathew’s finger to get a blood sugar reading.

A JDRF-funded clinical trial is examining whether a drug currently (ustekinumab; pronounced oos·teh·KIN·yoo·mab) used for the treatment of psoriasis (which affects the skin), Crohn’s disease (an inflammatory bowel disease), and other autoimmune conditions can also work for type 1 diabetes.

We’ve received many questions about the COVID-19 vaccination rollout in provinces and territories across Canada, and specifically at what stage people living with type 1 diabetes (T1D) should expect to receive theirs.

On January 15, 2021 Sernova announced that patients in their ongoing clinical trial show persistent islet function and clinically meaningful improvement in glucose control.

January 28, 2021 marks this year’s #BellLetsTalk day. This provides us the opportunity to talk freely and safely about mental health issues, and to raise awareness of the challenges faced by people living with T1D daily – and how JDRF Canada is looking to do more to address mental health in this community.